Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 5/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11909241 | 1.00 | HTT (0.43) | HTTGAASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL11908997 | 0.87 | HTT (0.44) | HTTGAASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL11909001 | 0.87 | HTT (0.44) | HTTGAASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL11909697 | 0.84 | HTT (0.41) | HTTGAASMN1; SMN2LMNAPRKCQ | |
| SCHEMBL11909699 | 0.84 | HTT (0.41) | HTTGAASMN1; SMN2LMNAPRKCQ | |
| SCHEMBL11909589 | 0.84 | HTT (0.46) | HTTGAASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL11909590 | 0.84 | HTT (0.46) | HTTGAASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL11909780 | 0.83 | PTGER4 (0.46) | HTTGAASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL11909786 | 0.83 | PTGER4 (0.46) | HTTGAASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL11909292 | 0.82 | HTT (0.49) | HTTGAASMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208827-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208827-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | HTT 4048/4885GAA 552/4885SMN1; SMN2 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.